GENENTECH, INC.;Board of Regents, The University of Texas System;德州大學
发明人:
Mark MERCHANT,Deepak SAMPATH,Marina Yurievna KONOPLEVA,Lina HAN
申请号：
HK19100995
公开号：
HK1259545A1
申请日:
2019.01.21
申请国别(地区):
HK
年份:
2019
代理人:
摘要：
The present invention is directed to a combination therapy involving a selective Bcl-2 inhibitor and a MEK inhibitor for the treatment of a patient in need of such a therapy. The patient in need of the combination therapy is suffering from cancer, such as acute myeloid leukemia.
